These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 21707497)

  • 1. Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation.
    Candolfi M; Kroeger KM; Xiong W; Liu C; Puntel M; Yagiz K; Muhammad AG; Mineharu Y; Foulad D; Wibowo M; Assi H; Baker GJ; Lowenstein PR; Castro MG
    Anticancer Agents Med Chem; 2011 Oct; 11(8):729-38. PubMed ID: 21707497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
    Hall WA; Vallera DA
    Neurosurg Focus; 2006 Apr; 20(4):E23. PubMed ID: 16709029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct cellular responses induced by saporin and a transferrin-saporin conjugate in two different human glioblastoma cell lines.
    Cimini A; Mei S; Benedetti E; Laurenti G; Koutris I; Cinque B; Cifone MG; Galzio R; Pitari G; Di Leandro L; Giansanti F; Lombardi A; Fabbrini MS; Ippoliti R
    J Cell Physiol; 2012 Mar; 227(3):939-51. PubMed ID: 21503892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral therapy of glioblastoma multiforme using genetically engineered transferrin for drug delivery.
    Yoon DJ; Kwan BH; Chao FC; Nicolaides TP; Phillips JJ; Lam GY; Mason AB; Weiss WA; Kamei DT
    Cancer Res; 2010 Jun; 70(11):4520-7. PubMed ID: 20460527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
    Han J; Puri RK
    J Neurooncol; 2018 Feb; 136(3):463-474. PubMed ID: 29168083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug delivery approaches for the treatment of glioblastoma multiforme.
    Fakhoury M
    Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1365-73. PubMed ID: 26046399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures.
    Joshi BH; Leland P; Asher A; Prayson RA; Varricchio F; Puri RK
    Cancer Res; 2001 Nov; 61(22):8058-61. PubMed ID: 11719427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic therapies in glioblastoma multiforme.
    McNamara MG; Mason WP
    Expert Rev Anticancer Ther; 2012 May; 12(5):643-54. PubMed ID: 22594899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of Therapies for Glioblastoma (GBM) Using Nanoparticle-based Delivery Systems.
    Wiwatchaitawee K; Quarterman JC; Geary SM; Salem AK
    AAPS PharmSciTech; 2021 Feb; 22(2):71. PubMed ID: 33575970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging of convection enhanced delivery of toxins in humans.
    Mehta AI; Choi BD; Raghavan R; Brady M; Friedman AH; Bigner DD; Pastan I; Sampson JH
    Toxins (Basel); 2011 Mar; 3(3):201-6. PubMed ID: 22069706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
    Joshi AD; Loilome W; Siu IM; Tyler B; Gallia GL; Riggins GJ
    PLoS One; 2012; 7(10):e44372. PubMed ID: 23056179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged survival upon ultrasound-enhanced doxorubicin delivery in two syngenic glioblastoma mouse models.
    Kovacs Z; Werner B; Rassi A; Sass JO; Martin-Fiori E; Bernasconi M
    J Control Release; 2014 Aug; 187():74-82. PubMed ID: 24878186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer drug-loaded hydrogels as drug delivery systems for the local treatment of glioblastoma.
    Bastiancich C; Danhier P; Préat V; Danhier F
    J Control Release; 2016 Dec; 243():29-42. PubMed ID: 27693428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deciphering the Role of Glutamate Signaling in Glioblastoma Multiforme: Current Therapeutic Modalities and Future Directions.
    Mollazadeh H; Mohtashami E; Mousavi SH; Soukhtanloo M; Vahedi MM; Hosseini A; Afshari AR; Sahebkar A
    Curr Pharm Des; 2020; 26(37):4777-4788. PubMed ID: 32493186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme.
    Rustamzadeh E; Li C; Doumbia S; Hall WA; Vallera DA
    J Neurooncol; 2003 Oct; 65(1):63-75. PubMed ID: 14649886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain.
    Oh S; Tsai AK; Ohlfest JR; Panoskaltsis-Mortari A; Vallera DA
    J Neurosurg; 2011 Jun; 114(6):1662-71. PubMed ID: 21294620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma.
    Wykosky J; Hu J; Gomez GG; Taylor T; Villa GR; Pizzo D; VandenBerg SR; Thorne AH; Chen CC; Mischel PS; Gonias SL; Cavenee WK; Furnari FB
    Cancer Res; 2015 Jan; 75(2):394-404. PubMed ID: 25432173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of CD44 in glioblastoma multiforme.
    Mooney KL; Choy W; Sidhu S; Pelargos P; Bui TT; Voth B; Barnette N; Yang I
    J Clin Neurosci; 2016 Dec; 34():1-5. PubMed ID: 27578526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STAT3 as a Therapeutic Target for Glioblastoma.
    Liu Y; Li C; Lin J
    Anticancer Agents Med Chem; 2010 Sep; 10(7):512-9. PubMed ID: 20879983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular pathways and potential therapeutic targets in glioblastoma multiforme.
    Wardak Z; Choe KS
    Expert Rev Anticancer Ther; 2013 Nov; 13(11):1307-18. PubMed ID: 24168050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.